RxDoctor Payments Data

Stephen Bashford

Optometrist · Arvada, CONPI 1962492140

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (34.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Alcon accounts for 86.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $3,251 and has fallen 89.2% since, to $353 in 2025. Among optometrist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,215in general payments, 2019–2025

Across 128 payments — averaging $71.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$8K
  • Bausch & Lomb Americas Inc.$394
  • Maculogix, Inc.$182
  • Johnson & Johnson Vision Care, Inc.$133
  • AbbVie$121
  • Sun Pharmaceutical Industries Inc.$103
  • plus $361 from 12 others

What the payments were for

  • Consulting fees$5706%
  • Speaking & faculty fees$3,00033%
  • Travel & lodging$2,44727%
  • Food & beverage$3,16734%
  • Gifts$190%
  • Entertainment$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,215 in reported general payments places this provider in the 95th percentile of 1,025 optometrist providers in Colorado.

See all optometrist providers in Colorado

Medicare billing

Part B allowed, 2024
$43,583
Medicare patients
186
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$49,948
LumiganBimatoprost50$35,131
Travoprost30$6,719
Brinzolamide13$2,285
Latanoprost156$1,955
Tobramycin-DexamethasoneTobramycin/Dexamethasone18$856
Brimonidine Tartrate14$516
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat38$390
Timolol Maleate35$311
Dorzolamide Hcl12$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$121$85,07894 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,025 optometrist providers in Colorado.

Other optometrist in Arvada

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →